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Abstract
The release of membrane-bound vesicles from cells has been increasingly recognized as a 
mechanism for intercellular communication. Extracellular vesicles (EVs) are also produced by 
virus-infected cells and are thought to be involved in intercellular communication between 
infected and uninfected cells. Viruses, in particular oncogenic viruses and viruses that establish 
chronic infections, have been shown to modulate the production and content of EVs. Viral 
microRNAs, protein and even entire virions can be incorporated into EVs, which can impact 
immune recognition of viruses or modulate neighboring cells. In this Review, we will discuss the 
roles that EVs have during virus infection to either promote or restrict viral infection in target 
cells. We will also discuss our current understanding of the molecular mechanisms that underlie 
these effects, the potential consequences for the infected host, and possible future diagnostic 
applications.
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The release of membrane-bound vesicles from cells has been increasingly recognized as a 
mechanism for intercellular communication. In this Review, Raab-Traub and Dittmer discuss the 
roles that extracellular vesicles have during virus infection.
Introduction
Extracellular vesicles (EVs) are secreted from healthy, malignant and virus-infected cells. 
EVs are either released directly from the plasma membrane or during fusion between 
multivesicular bodies (MVB) and the plasma membrane1,2. EVs released from the MVB are 
termed exosomes. Similar to EVs, viruses can be released through multiple pathways 
including the plasma membrane and/or via the MVB route (reviewed in 3). For example, 
some retroviruses such as human immunodeficiency virus type 1 (HIV-1) assemble at the 
inner leaflet of the plasma membrane whereas other retroviruses, such as Mason-Pfizer 
monkey virus (MPMV) assemble in the cytoplasm first before trafficking to the cell surface 
(reviewed in 4). Some viruses are non-enveloped and do not require an envelope for 
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infectivity, but nevertheless can be incorporated into EVs. For example, hepatitis A virus 
(HAV) was recently shown to be secreted within EVs that can potentially transmit to 
uninfected cells within an infected individual5,6. Other enteroviruses may package up to ~20 
particles within a single membrane vesicle and bud without destroying the cell 7. Autophagy, 
which is usually thought of as a regulated mechanism to provide nutrients through digestion 
of intracellular organelles, is utilized in different ways in the egress of multiple viruses. Not 
only do some enteroviruses exit infected cells in packages wrapped into autophagic 
membranes, autophagic membranes form part of the envelope for herpesviruses, para and 
orthomyxoviruses 8. Lipidated LC3, an essential mark of autophagosomes, has been 
detected in extracellular microvesicles containing coxsackie virus. Additionally, the 
exosome marker flotillin-1 was also found in these vesicles suggesting that picornaviruses 
utilize autophagy related EV release as one pathway for their exocytosis 9
EVs are thought to have an important role in virus infection and a number of interactions 
between viral components and cellular components that are required for the biogenesis of 
EVs have been reported. Therefore, a critical comparison of virus particles with EVs may 
lead to a greater understanding of both viral life cycles and the function of EVs.
Due to their small size and similar biochemical composition, viruses and EVs can have 
similar biophysical properties. The term exosome is used if EVs are ≤100 nm in diameter 
and originate from the MVB, microvesicle if the diameter is 100–1,000 nm or apoptotic 
body if the diameter is >1,000 nm. Similarly, viruses range in diameter from 30 nm for 
poliovirus, 120–140 nm for herpesviruses and 200–300 nm for poxviruses (reviewed in 10). 
This similarity in biophysical properties increases the difficulty in obtaining pure 
populations of EVs that are not contaminated with viruses and vice versa, which makes it 
difficult to determine the precise composition of EVs and virions (Box 1). The identification 
and characterization of virion-associated proteins has been the subject of intense study over 
many years11, whereas the identification of proteins that are associated with EVs has been 
more recent. Recent studies have identified some key components of EVs that can be used as 
markers to identify and assess the purity EVs (Table 1); however, it is important to recognize 
that not all EVs carry all of these markers12. In the context of virus infection, viral RNAs 
and proteins have been found in EVs13–16, which could be the result of selective 
incorporation of specific RNAs and these proteins or alternatively, reflect the total 
intracellular constituents. Further work is required to determine the precise composition of 
EVs. The development of mass spectrometers with enhanced specificities and sensitivities 
compared to existing instruments will undoubtedly advance our understanding of the 
composition of EVs. Further work is also required to optimize the purification of EVs and 
therefore careful consideration is required when attributing functional phenotypes to EVs in 
the context of virus infection.
Box 1
Differentiating EVs from virions
The purity of any preparation of EVs is determined by measuring light-scatter and 
Brownian motion and by electron microscopy (Figure 2). More recently, flow cytometry-
based methods have been introduced, but the small size of EVs makes it difficult to detect 
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EVs using conventional instruments. EVs can be isolated by size-exclusion 
chromatography, differential ultracentrifugation, density flotation, crowding agents, flow-
cytometry or affinity purification (Table 2). Each method has specific advantages158. 
Size-exclusion chromatography is the best method for preserving the structure of 
EVs159–161, though it does not separate virions from EVs11,151,162. The use of crowding 
agents, such as PEG3000 followed by precipitation is the fasted way to isolate and 
concentrate EVs for subsequent applications, however, this approach also enriches 
soluble proteins and contaminants that are not part of EVs. When profiling miRNAs in 
EVs it is important to consider that are Ago-associated miRNAs are present in serum163. 
These Ago-miRNA complexes also co-purify with EVs when only crowding agents are 
used, however, this problem can be circumvented by using affinity-based purification 
methods. Affinity purification using magnetic beads enables the high-throughput 
purification of EVs on robot platforms and it is able separate EVs from viruses 13. For 
example, EVs from B cell lymphomas are enriched for B cell surface antigens, including 
CD81 and CD63, which can be used to affinity purify EVs using antibodies that bind 
these proteins 164. However, this approach will exclude populations of EVs which do not 
have the particular surface marker used for affinity purification, but which may 
nevertheless contribute biological functions of EVs12.
Table 2
Method Mechanism Input volume Virion co-purification
Differential ultracentrifugation Density and size 35 ml Yes
ExoQuick (SBI Biotech Inc.) Precipitation 250 μl Yes
Total EV (Invitrogen Inc.) Precipitation 250 μl Yes
PEG-2000 Precipitation 250 μl – 250 
ml
Yes
CD63 magnetic beads Bead-based surface marker 1 – 35 ml No
Composite magnetic beads Bead-based surface 
markers (n=5 markers)
100 μl – 1ml No
Size exclusion chromatography Size-bases isolation 100 μl – 35 
ml
Yes
Density flotation (for example, 
Iodixanol)
Density 35 ml Yes
Research into understanding the role of EVs in viral infections is driven to a large extent by 
commercial interests in biomarker development. For example, miR-122 that is incorporated 
into EVs during acute liver injury could be used as a biomarker to determine the extent of 
damage to the liver 17–19. The miR-122 is the most abundant miRNA in liver cells and 
perhaps reflecting this abundance it is incorporated into EVs. The correlation between the 
levels of miR-122 and alanine aminotransferase, an enzyme that is also released when the 
liver is damaged, has been established in the clinic. Therefore, miR-122 could be used as an 
alternative, more specific biomarker to alanine aminotransferase in the clinic. Notably, 
miR-122 is also required for HCV replication and therefore it is an attractive drug target for 
the development of new therapies against HCV 20–22. The success of such therapies could be 
determined by minimally invasive profiling of EVs and plasma miR-122 levels since 
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miR-122 would add information about liver cell status beyond viral load. The use of highly 
multiplexed assays that are able to detect multiple miRNAs and viruses, next-generation 
sequencing and mass spectrometry will help drive the research of EVs for diagnostic 
applications
Studying EVs in the context of virus infection has been crucial in demonstrating the 
potential contribution of EVs to viral pathogenesis 23, as EVs from virus-infected cells often 
transfer viral components to uninfected cells, for example, Epstein-Barr virus (EBV) LMP1 
protein and viral miRNAs16,24. This intercellular transfer of viral cargo occurs in the 
absence of cell-to-cell fusion, cellular synapses or membrane nanotubes25–27 and 
represents the existence of a host transfer mechanism that occurs in the absence of virus 
spread. Roles for intercellular transport by EVs have been described, for example, in 
mediating cross presentation for T cells28–30 and in mediating synaptic transmissions31. 
Many of the vesicles that are used during these processes share biogenesis features and 
fusion mechanisms that are similar to EV and viruses. In the context of cross-priming, 
however, the vesicles tend to stay in the immediate microenvironment, such as the 
lymphnodes, and are not found circulating systemically in body fluids.
In this Review we will focus on the identified molecular and biological properties of EVs 
released from virally infected cells and consider how the virally modified EVs may either 
facilitate viral infection or promote resistance to immune recognition by antibodies or 
inhibition of innate immunity activation within recipient cells. In particular we focus on 
human viral infections with HIV, HAV, and HCV, and the two herpesviruses EBV and 
Kaposi Sarcoma-associated herpesviruses (KSHV). It is in the context of these chronic, 
persistent, and latent infections that EVs have been most thoroughly explored.
Biological roles for EVs in viral infections
Oncogenic viruses and viruses that are able to establish long-term persistent infections have 
been shown to alter the content of EVs, which has been hypothesized to facilitate infection 
and contribute to persistence and pathogenesis. Persistent or chronic infections are 
characterized by low levels of viral replication and circulating virus particles (~101–104 
particles/ml) 3. By contrast, during latent infections viruses cannot be detected in 
circulation. Latency has a defining role in herpesvirus and lentivirus infections. In the case 
of latent herpesvirus infections, viral miRNAs can be detected within EVs at times when 
conventional viral load assays are negative13,16,24. In the case of HIV-1 the viral protein Nef 
has been found in EVs that circulate in infected individuals32–34. Systemic circulation of 
viral proteins in EVs enables these viruses to modulate host cells without exposing viral 
proteins or virions to the immune system. By contrast, rapidly replicating viruses, such as 
Ebola virus, influenza A virus or Zika virus accumulate to high titers (106–1011 particles/ml) 
in blood within days of primary infection. For these viruses, the viral titer is similar to the 
number of circulating EVs (1010–1012 particles/ml) 35. Despite these high viral titers, it is 
possible that EVs that carry viral proteins or nucleic acids could modulate host cells, for 
example by determining their permissiveness to infection.
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The biological function of EVs in the context of viral infections can affect viral infection in 
two opposing ways (reviewed in 23,36–38). On the one hand, EVs can either modulate 
recipient cells by promoting viral replication or, on the other hand, EVs can restrict viral 
replication through triggering host immune responses.
Properties of EVs
Biogenesis
EVs are small membrane-bound carriers of intracellular cargo that are derived from MVBs 
or from the plasma membrane (Figure 1). Unlike virus particles, the membranes of EVs do 
not enclose a structured core, such as a capsid. Specific properties of EVs define and 
distinguish EVs from other types of microvesicles10. The assembly of EVs is an active, 
energy dependent and regulated process39,40. This process has been shown to specifically 
require sphingomyelinase41 and components of the endosomal sorting complex required for 
transport (ESCRT) machinery. The content of EVs is determined by the protein and RNA 
composition of the cells from which they are derived. The composition of EVs frequently 
reflects the relative abundance of contents within the EV-producing cell. Thus EVs that are 
derived from virus-infected cells contain highly expressed viral miRNAs13,16,24. In addition, 
several recent studies have provided evidence for differential loading, where the relative 
abundance of the EV miRNAs is distinct from that within the producing cell16,24,42–45.
The budding of EVs into MVBs requires the ESCRT proteins tumor susceptibility gene 101 
protein (TSG101) and Alix (also known as programmed cell death 6-interacting protein), 
which are also known markers of EVs2. TSG101 and Alix are also required for ESCRT-
dependent budding of enveloped viruses from the plasma membrane, such as HSV-146, 
therefore it is difficult to determine whether these are specific EVs as thus they do not 
conclusively establish EV originating from MVBs or the plasma membrane using these 
proteins as markers. Other membrane proteins that localize to lipid rafts in the plasma 
membrane, including tetraspanins such as CD63 and CD81, are also enriched in EVs. This 
process involves palmitoylation 47 which has been shown to be required for the 
incorporation of the EBV protein LMP1. LMP1 is enriched in lipid rafts and in EVs48. 
Depending on the experimental approach and cell line, other proteins such as Sortillin 
(SORT1), Synthenin-1 (SDCBP), or Syndecan-1 (SDC1) have also been found to have a role 
in the biogenesis of EVs49–51.
The Rab family of small GTPases regulates multiple steps in the trafficking of vesicles to 
distinct endocytic compartments and they also function in docking of the MVB to the 
plasma membrane (Figure 1). For example, Ras-related protein Rab-11A and Rab35 
function during the recycling and sorting endosomes, whereas Rab27A and Rab27B are 
essential for the secretion of EVs52. It is likely that some viruses modulate this complex 
process to facilitate viral entry, trafficking, and egress. Rab6 and Rab7 also affect the flux 
between lysosomes and autophagosomes and could contribute to determining the content of 
EVs53–55. Multiple viruses affect the expression of ESCRT and Rab GTPases to promote 
viral entry and egress and are therefore likely to modulate the content of EVs56.
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Additionally, it is known that members of the Rab family of GTPases also interact with 
members of the Ral family of GTPases and function during intracellular trafficking. It has 
been shown in Caenorhabditis elegans that Ral1 (the homologue of human RALA and 
RALB) regulates both MVB biogenesis and the secretion of EVs57. Activated Ral1 
associates with syntaxin 5 (SYX5), a soluble N-ethylmalemide-sensitive fusion protein 
attachment protein receptor (SNARE) complex protein, at the plasma membrane and is 
required for the secretion of EVs. Interestingly, SYX5, is also required for the release of 
human cytomegalovirus (HCMV) and syntaxin-4, another SNARE complex protein has been 
found to regulate HCV release58,59. Additional SNARE complex proteins have also been 
shown to interact with herpesvirus glycoproteins to promote release60. These examples 
demonstrate that viruses co-opt the cellular vesicular transport system during egress and 
therefore, they are also likely to modulate the content and secretion of EVs through similar 
interactions.
EV Uptake
Viruses use cell surface receptors to initiate fusion with the plasma membrane and are 
known to use specific receptors to target specific cell types. This receptor-specificity 
determines their cellular tropism and is a distinguishing feature of EVs, which have the 
ability to enter a greater variety of cell types than viruses. Using fluorescent dyes that are 
incorporated into EVs, it was demonstrated that membranes of EVs can fuse with cell 
membranes16,24,61,62. Most cell types that have been tested can fuse with EVs and therefore 
EVs can be used to deliver cargo to a wide variety of cell types. This process is analogous to 
cationic lipid-mediated transfection approaches. In some cases, EVs use specific receptors 
for entry12,63 and therefore the fusion of EVs with cellular membranes can be specific. For 
example, EVs from EBV-infected cells that express the viral glycoprotein gp350, or EVs 
that are engineered to express gp350, specifically target B cells that express the viral entry 
receptor CD21 and can block EBV infection of naïve B cells61,64.
Heparin is involved in the initiation of host cell entry for many viruses, including 
retroviruses and herpesviruses65. It is a glycosaminoglycan that binds almost all viral 
envelopes. Thus, exogenous heparin or heparin beads can inhibit virion attachment through 
competitive binding. Cell surface-bound heparin is thought to concentrate virions prior to 
specific receptor and co-receptor engagement. It is also thought to have a role in the entry of 
EVs66, though the fusion of EVs with the plasma membrane can occur at heparin 
concentrations that block herpes simplex virus 1 (HSV-1) entry. This provides an 
experimental tool to separate virion effects from EV phenotypes, as virus entry, even of non-
infectious or defective HSV-1 particles, can be blocked by heparin. It suggests that EVs use 
different mechanisms for entry to cells compared to most viruses.
Similarly, annexin A5 (and potentially other annexin family members) mediates the fusion 
of EVs to the plasma membrane through binding to phosphatidyl-serine67. Importantly, 
Annexin A5 does not antagonize virus entry and thus can also be used to distinguish EV-
mediated phenotypes from virus particle or soluble molecule-mediated phenotypes. 
Although the biogenesis of virions and EVs are similar, EVs and virions likely use different 
mechanisms to enter cells.
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Integrins and integrin-binding matrix proteins, many of which contain a signature motif of 
arginine, glycine, and aspartic acid (RGD), have an important role in virus entry and their 
potential role in the entry of EVs is also beginning to be understood 68,69. They are thought 
to act as attachment factors or co-receptors that synergize with the primary receptor for virus 
entry. Both EBV and KSHV utilize integrins as a co-receptor for viral entry70. RGD 
peptides and anti-integrin antibodies can interfere with the attachment of virions and EVs to 
cells68,70 and affect signaling through the integrin homodimer and heterodimer and thus 
have pleotropic effects on cell physiology. For example, the anti-integrin antibody 
Etaracizumab is in clinical trials as anti-angiogenesis agent in non-virus associated cancers, 
because blocking integrin signaling can induce cell death.
Viruses have a strict requirement for cell-type specific receptors and co-receptors. These 
engage specific envelope glycoproteins and force large molecular rearrangements to expose 
the components of the viral fusion complex. Hence, hyper immune serum that was raised 
against virion components has clinical utility in blocking infection, for example, in treating 
patients that have been exposed to Ebola virus71. By contrast, entry of EVs is more 
promiscuous than viruses and clathrin-dependent, caveolae-dependent, 
macropinocytosis 56,62, phagocytosis, and lipid raft-mediated uptake72 have all been shown 
to contribute to the entry of EVs (reviewed in 63).
EV-meditated functions
Much of what we know about the physiological function of systemically circulating EVs 
derives from studies that have analyzed their contribution to cancer metastasis 73–76. It was 
found that EVs released from tumor cells can modulate cells in the surrounding 
microenvironment and drive distant metastasis by modulating stromal cell growth, cell 
migration, induce growth factor secretion, and vascular permeability. A supportive 
microenvironment, for instance by providing growth factors and extracellular matrix 
attachment opportunities and increased endothelial cell permeability, are also essential for 
systemic virus spread. In the following sections we will review how EVs contribute to viral 
infection
HCV—HCV is a member of the Flaviviridae. It is distinct from the arbovirus members of 
this virus family as it is transmitted by blood-to-blood contact or through sexual intercourse, 
rather than by an insect vector. HCV virions are enveloped and are smaller than EVs (~50 
nm in diameter in contrast to ~ 100 nm of EVs)77. EVs isolated from HCV-infected human 
hepatoma cell lines have been shown to contain HCV78,79. Some of the subgenomic HCV 
RNA co-localizes with CD81 and CD63 (markers of EVs). The HCV E2 protein was also 
found to co-localize with CD81 in EVs and EVs were found to transmit viral RNA to 
uninfected cells79–81. CD81 is the dominant HCV co-receptor82–84, therefore it is likely that 
HCV virions are incorporated into EVs by their interaction with CD81. HCV RNA that is 
transmitted by EVs induces an innate interferon (IFN)-alpha response in neighboring 
dendritic cells (DCs). This is in contrast to natural HCV infection, which also delivers viral 
RNA to cells, but down-regulates TLR and RLR signaling through the action of the viral 
NS3/4 protease. Therefore by specifically transmitting viral RNA, but not viral proteins, 
which antagonize innate immunity, EVs may provide a protective function for uninfected 
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cells in the immediate microenvironment during infection. Systemically circulating EVs that 
contain HCV virions may have a pro-viral role, as HCV has been shown to spread in the 
presence of neutralizing antibodies78,85. This spread may be facilitated by the masking of 
viral proteins in the EVs (Figure 2, panel A). Such a strategy of host evasion in which 
persistent viruses, such as HCV and more prominently HAV (see below), to escape the 
evolutionary selection pressure of neutralizing antibodies by being incorporated in EVs may 
be widespread. The carriage of HCV virions in EVs also suggests that HCV could enter a 
range of different cell types, in addition to hepatocytes, through EV-mediated fusion in 
which infection would not be dependent on the expression of a specific viral receptor.
HAV—HAV, a non-enveloped picornavirus, is the cause of acute enterically transmitted 
hepatitis and replicates efficiently in the liver. HAV rapidly replicates in susceptible cells and 
viral particles are released from these cells, however, no cytopathic effect has been observed. 
RNA-containing proteinaceous particles (density of 1.22 – 1.28 g/ml) represent the major 
species of HAV in feces 6. HAV can be neutralized by antibodies that are elicited by the 
current HAV vaccines. It has been shown that HAV can be released from cells in host-
derived membranes at a density of 1.06–1.10 g/ml5. These EVs that contain HAV are 
infectious and circulate in the blood of infected humans, whereas non-enveloped virus has 
only been found in feces (Figure 2, panel B)6. Coxsackie B virus and Enterovirus 71 
(EV71), two other picornaviruses, have also been found in EVs7,86,87.
Two hypotheses have been made to explain importance of EV-encapsulated picornaviruses 
as a biological mechanism rather than a side product of cellular inefficiencies6. Firstly, the 
envelopment of HAV by host membranes may expand the tropism of the viruses as now EV 
surface proteins rather than the viral surface proteins engage the target cells. This may 
provide an additional route for HAV to spread within the liver and systemically to distant 
organs, such as the spleen, and lymph nodes, which function to filter and survey systemic 
fluids 3. Second, the acquisition of a host membrane by HAV demonstrates that some non-
enveloped viruses can acquire an envelope that is devoid of viral transmembrane proteins 
and thus provides evidence for a second, alternative egress pathway. This suggests that the 
egress that is mediated by EVs would be distinct from the normal egress route. The 
acquisition of a host-derived membrane could also affect antibody recognition of HAV 
capsid proteins and may allow persistence and spread in the presence of neutralizing 
antibodies.
HIV—HIV is a human retrovirus that contains an RNA genome and acquires its envelope 
from the cellular plasma membrane, where it buds from areas that are enriched in the viral 
Gag protein. After a month-long period of acute replication (105–107 viral particles/ml), 
HIV establishes a latent infection, which slowly progresses to acquired immune deficiency 
syndrome (AIDS) over a period of years in untreated individuals as the virus depletes CD4+ 
T cells. It is believed that during viral latency (≤ 5 * 101 viral particles/ml in plasma), HIV 
directly and indirectly modulates the immune system, leading to chronic pathology. Many of 
these indirect effects on the immune system are observed even in patients on anti-retroviral 
therapy. Various hypotheses for this phenomenon have been proposed, including a role for 
EVs. In addition, soluble viral proteins, such as HIV Tat as well as secondary events to 
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immune compromise, such as extended LPS translocation may contribute to this 
phenotype 88,89 (reviewed in 36). HIV assembly and the biogenesis of EVs have many 
similarities90–92. These similarities impair the biochemical and physical separation of EVs 
away from virions, which include mature, immature, and even defective particles. The 
molecular pathogenesis of HIV suggests potential EV-mediated effects on neighboring cells 
(Figure 2, panel C), because HIV kills more abortively infected or uninfected T cells than 
infected cells 93–96. HIV infected cells may also release EVs with trapped HIV virions94–97.
More importantly, HIV encodes a number of accessory proteins, such as Vif98, which 
interfere with the cellular antiviral response. These pro-viral proteins may also be carried by 
EVs to prime neighboring cells to promote infection, in what is called the ‘Trojan Horse’ 
hypothesis 23,36. Conversely, cellular anti-viral factors that are carried via EVs could 
facilitate an antiviral response in neighboring cells99. Additionally, EVs packaged with viral 
proteins may function to introduce viral proteins and would activate B cells and T cells 
through endosomal presentation of proteins, a process termed cross priming, rather than 
endogenous synthesis and presentation within MHC molecules. Thus these immune cells 
would become specifically activated without actual viral infection 100,101.
It is known that HIV infection changes the repertoire of miRNAs within infected cells102–104 
and considering that miRNAs can be packaged into EVs13, the EVs from HIV-infected cells 
may contain distinct miRNAs compared to EVs from uninfected cells. In the context of 
AIDS-defining malignancies, such as Kaposi’s sarcoma, EVs isolated from HIV-infected 
patients have distinct miRNAs profiles prior to and concurrent with lesion 
development13,105. Initially, HIV was thought to encode miRNAs106, but these observations 
have since been questioned107,108. It is becoming clear that miRNAs with Drosha-dependent 
hairpin-looped precursors are not the only small RNAs that can be transcribed from RNA 
virus (including retroviruses) genomes109–111 and some of these RNA species have been 
found in EVs112. The potential roles of miRNAs (as defined by their biogenesis and 
structural composition) or other small RNAs that do not fit the classical definition of 
miRNAs to EV function is a new area of investigation that is likely to reveal new properties 
that affect viral infection and pathogenesis.107,108,113.
EVs from HIV-infected cells contain the viral protein Nef 32–34. In addition, soluble HIV Tat 
protein circulates in interstitial spaces, blood, and mucosal barriers and can perform 
biological activities, such as promoting angiogenesis and endothelial cell 
reprogramming89,114–116. Soluble Tat has a fusogenic peptide sequence that enables its 
efficient uptake into cells117,118. Since the HIV Tat protein would not need to be 
incorporated into EVs to enter cells, the biological relevance of the incorporation of Tat into 
EVs remains unclear. HIV Nef associates with membranes and with members of the 
vesicular trafficking system, such as Alix and others 119,120. Nef can be incorporated into 
EVs and may modulate the contents of EVs including miRNAs32–34,121; however, others 
have contested these findings as the level of Nef in EVs is at the limit of detection122. In 
sum, HIV provides an example of how latent viruses may use EVs to maintain a susceptible 
host environment over long periods of time during which no virions are detectable.
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EBV—EBV, a gamma herpesvirus, was the first human tumor virus to be identified and a 
major human pathogen3. EVs containing viral proteins were first shown to be produced from 
B cells that were infected with EBV. The major EBV oncoprotein, latent membrane protein 
1 (LMP1), was identified in EVs secreted from EBV infected cell lines123. LMP1 is required 
for B lymphocyte transformation (reviewed in 124). The incorporation of this protein into 
EVs has not only been demonstrated in B cells and epithelial cells that were cultured in vitro 
but has also been detected in exosomes in the serum of patients with EBV-associated tumors 
and in the serum from mice carrying nasopharyngeal carcinomas (NPCs)16,125. The 
interaction of LMP1 with the tetraspannin CD63 may contribute to the selective 
incorporation of LMP1 into EVs48,126 as does selective palmitoylation of LMP147. 
Additionally, LMP1 is known to localize to lipid rafts within membranes and lipid rafts are 
present within the membranes of EVs 127. It is possible that the presence of LMP1 in lipid 
rafts may contribute to enrichment of LMP1 within MVBs and subsequently enriched within 
exosomes.
EVs secreted from B cells containing LMP1 inhibit T cell proliferation and NK cell 
cytotoxicity123,128. EVs that are secreted from EBV-infected NPC cells also contain 
galectin-9, which is thought to contribute to these immunosuppressive effects128–130. It has 
long been known that EBV-infected NPC tumors are infiltrated with T cells that are 
apparently nonfunctional as they do not kill tumor cells or impair tumor growth. This lack of 
activity may reflect the abundant secretion of EVs during EBV infection, thus representing 
another viral immune evasion strategy.
Importantly, LMP1-containing EVs have been shown to deliver activated signaling proteins 
into uninfected cells131. This potentially important feature of EVs was revealed in studies 
that showed that the epidermal growth factor receptor (EGFR), which is highly induced by 
LMP1, was also abundant in LMP1-containing EVs16. LMP1 has also been shown to 
increase PI3CA levels within lipid rafts and within EVs. The delivery of LMP1 and EGFR 
and PI3CA through EVs induced growth stimulating signaling pathways in recipient cells, 
including the activation of the PI3kinase target, Akt1, and ERK1131. An early study revealed 
increased incorporation of fibroblast growth factor 2 (FGF2) from LMP1 expressing cells 
into EVs which could potentially affect the tumor environment through the direct growth 
stimulation of infected cells or supporting stromal cells132. Additionally, it has been 
demonstrated that LMP1 activates HIF1-alpha, which is also transferred by EVs into 
recipient cells and can activate HIF1-alpha targets133. HIF1-alpha is the major 
transcriptional regulator in hypoxic conditions that are characteristic of many tumors and 
could promote survival of tumor cells in an anoxic environment. An important target of 
HIF1-alpha is the vascular endothelial growth factor, which induces angiogenesis. Thus, 
through the transfer of EVs, EBV can affect the growth of neighboring cells. It is also known 
that within tumors that are caused by EBV infection, not all cells express LMP1. Therefore 
the secretion and uptake of LMP1 into cells that do not express LMP1 could affect the 
growth of additional tumor cells. This may be particularly important in the pathogenesis of 
NPC where not all cells express detectable levels of LMP1.
LMP1 may also modulate the selective sorting of proteins into the exosomal pathway, 
suggesting that EBV manipulates these pathways for intercellular communication. The 
Raab-Traub and Dittmer Page 10
Nat Rev Microbiol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
possibility of LMP1-mediated specific effects on the content of EVs was revealed from 
quantitative proteomics and 2-dimensional gel analysis of EVs that were purified from B-
cell lines that were uninfected, infected with EBV, KSHV, or with both viruses131. Analysis 
of LMP1-positive versus LMP1-negative cell lines revealed 217 protein spots with 
significantly different expression (P < 0.05). Principal component analysis to identify the 
distinguishing features among the EVs from these different cells lines revealed that LMP1 
was a major determinant for the variance between samples. This strongly suggested that 
LMP1 had an effect on the exosomal protein content and provided additional evidence for 
specific viral effects on this process.
Spectral counting analysis also indicated that both KSHV and EBV had distinct effects on 
the content of EVs and that these effects reflected cellular changes that occur in infected 
cells131. Gene ontology pathway analyses of proteins that were identified in EVs that were 
derived from infected cells predicted that EVs from EBV and KSHV infected cells likely 
modulate cell death and survival, ribosome function, and protein synthesis. Analyses of the 
content of EVs from infected cells also indicated that KSHV EVs could affect cellular 
metabolism and that EVs from EBV infected cells could activate cellular signaling mediated 
by integrins, actin, interferon, and NF-kB through the transfer of critical regulatory proteins 
in these pathways.
An additional, novel finding was that EBV-encoded miRNAs were also detected in EVs that 
were secreted from EBV infected cells and that these viral miRNAs could then be 
transferred to uninfected recipient cells16,24. Importantly, the viral miRNAs were shown to 
specifically decrease previously identified viral miRNA targets, thus providing evidence of 
functional delivery of miRNAs through EVs24. This transfer also likely occurs in vivo as 
uninfected B cells that were isolated from patients with NPC contain viral miRNAs. 
Interestingly, EVs from NPCs have distinct patterns of EBV miRNA abundance compared to 
the intracellular levels in the producing cells16. This observation supports the hypothesis that 
there is selective sorting of specific miRNAs into EVs.
In addition to viral proteins and miRNAs, 5′pppEBER1, a small non-coding viral RNA, has 
also been found in EVs that are secreted from EBV infected cells134. EBER1 is the most 
abundant viral RNA in infected cells and 5′pppEBER1 enhances the immune function of 
dendritic cells. This unusual finding may indicate that EVs contribute to autoimmune 
diseases, such as lupus, that have been linked to EBV infection3. Overall, these findings 
suggest that EBV modulates EVs to specifically secrete viral and cellular proteins and 
miRNAs that likely contribute to intercellular communication and affect the function of 
uninfected cells. Modulating the content of EVs could be important for affecting the tumor 
environment by inducing cell growth, promoting angiogenesis, and inhibiting immune cell 
function, and also for potentiating metastasis.
KSHV—KSHV causes Kaposi’s sarcoma and a variety of hyperplastic and neoplastic B cell 
disorders, such as primary effusion lymphoma (PEL). PEL usually present with liquid 
effusions without tumor masses in serous body cavities. Cell-free, primary PEL fluid is 
highly enriched in tumor-derived EVs13. Primary KSHV infection is asymptomatic in the 
healthy host and results in lifelong latency. In rare cases, immune reconstitution 
Raab-Traub and Dittmer Page 11
Nat Rev Microbiol. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
inflammatory syndrome follows, which is associated with severe disease flares and clinical 
symptoms consistent with infection and inflammation. Common to all Kaposi’s sarcoma 
pathology is neo-angiogenesis and the infiltration of the environment around the tumor cells 
with uninfected, non-transformed host cells, such as endothelial cells and macrophages. 
After hemangioma, Kaposi sarcoma is the most angiogenic cancer and therefore the study of 
KSHV can be useful in understanding the interaction between EVs and endothelial cells. 
KSHV angiogensis is driven by paracrine effectors such as soluble cytokines and the growth 
factors vascular endothelial growth factor 1 (VEGF-1) and platelet derived growth factors 
PDGF (1–4) 135. Initially, the paracrine drivers of Kaposi’s sarcoma were thought to be only 
soluble cytokines (for example, vascular endothelial growth factor and platelet derived 
growth factor or IL6). More recently EVs have been shown to mediate some of these 
phenotypes such endothelial cell remodeling, migration and proliferation independent of 
IL-6 13. PEL and Kaposi’s sarcoma tumor cells release large quantities of EVs, which drive 
endothelial cell proliferation and invasion in the presence of neutralizing antibodies to 
IL-6 13.
KSHV encodes multiple viral miRNAs136,137 and these viral miRNAs constitute up to 50% 
of all miRNAs in infected cells138. Viral miRNAs and mRNAs have been detected in virion 
preparations of almost all herpesviruses14,15,139. Viral miRNAs are also readily detected in 
Kaposi’s sarcoma-tumor derived EVs140. The levels of viral miRNAs in EVs are 10–100-
fold higher than what has been reported for virion-associated miRNAs. Owing to the similar 
biophysical characteristics of virions and EVs, it is unclear if reports of virion-associated 
RNAs reflect contamination by EVs.
Several lines of evidence have attributed phenotypes that had been attributed to miRNAs 
incorporated into virons to miRNAs incorporated into EVs. These include the biochemical 
separation of EVs by positive selection on anti-CD63 beads (a marker of EVs) (Figure 4), as 
well as genetic approaches, such as the detection of KSHV miRNA-containing EVs in 
KSHV-microRNA transgenic mice, which cannot produce virus 13. This suggests that during 
KSHV latency viral miRNAs can be incorporated into EVs via the same host cellular 
pathways that load host miRNAs into EVs. Similar to KSHV virions that contain a large 
proportion of the total pool of intracellular miRNAs, a large proportion of KSHV miRNAs is 
also incorporated into systemically circulating EVs13. The identity and abundance of 
miRNAs in EVs thus represents a snapshot of their cellular origin. A more active model 
hypothesizes that viral miRNAs and proteins are specifically and differentially loaded into 
EVs16,24,42–45.
KSHV infection changes many aspects of the physiology of the infected cell, including lipid 
metabolism and presumably vesicle biogenesis. The protein composition of EVs and their 
secretion is modulated during viral reactivation from PEL cell lines16, though KSHV 
proteins have not been detected in EVs131. The replication and maturation of KSHV is much 
slower compared to other viral infections3. In culture models of KSHV, the number of 
infectious virions is approximately 105 copies/ml, compared to 107 copies/ml for EBV or 
109 copies/ml for flaviviruses141. In Kaposi’s sarcoma patients, the viral titer ranges from 
103–105 copies/ml, whereas EBV or HCMV titers exceed 106 copies/ml in patients and viral 
titers during hepatitis virus infections range from 105–109copies/ml. We speculate that for 
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KSHV, preventing the accumulation highly immunogenic virions, and instead using host 
EVs to distribute viral miRNAs to neighboring cells represents a novel strategy to persist in 
the host (Figure 2, panel E). In this model, RNAs in EVs offer an evolutionary advantage 
for virus spread by priming neighboring cells for infection. KSHV infects and replicates 
primarily in endothelial cells. These need to be attracted and re-programmed to migrate 
towards the initially infected cell. PEL derived EVs that are secreted by PELs confer this 
property onto uninfected endothelial cells in culture through the transfer of viral miRNAs or 
even and protein coding RNAs 142,143. In sum, KSHV represents another example, by which 
the virus modulates the host local environment by releasing EVs through EV 
reprogramming. Interfering with EV the release of EVs during KSHV infection may 
therefore have the potential to limit virus spread or virus pathology.
Alphaherpesviruses and betaherpesviruses—Alphaherpesviruses, such as herpes 
simplex virus type-1 (HSV-1), and betaherpesviruses, such as HCMV, also influence the 
biogenesis pathway of EVs and use these pathways for egress144–146. Similar to the 
biogenesis of EVs, HCMV virion maturation is dependent on the ESCRT machinery and 
they contain cellular markers that are associated with EVs147,148. Some of the observed 
systemic and biological phenotypes that are associated with HSV-1 and HCMV infection, 
may be result of massive re-programming of MHC-I and MHC-II trafficking from the 
secretory pathway. HCMV replicates in a variety of cell types including endothelial cells 
that line the blood and lymphatic vasculature and can cause graft rejection in organ 
transplantation. EVs that are released from HCMV-infected endothelial cells can exacerbate 
allogeneic graft rejection 149.
More recently, it was shown that the immune sensor stimulator of interferon genes protein 
(STING) is incorporated into EVs that are secreted from HSV-1 infected cells and that the 
STING ligand cyclic GMP-AMP synthase (cGAMP) is present in EVs that are released from 
cells that are infected with murine cytomegalovirus150,151. The cGAMP nucleotide triggers 
the recognition of foreign molecules via STING and also augments RIG-I and TLR 
signaling, leading to a strong interferon response. It is possible that introducing cGAMP into 
cells via EVs may trigger an antiviral response in neighboring cells152. This represents 
perhaps the most direct demonstration that cellular EVs can play an anti-viral and pro-host 
role.
HSV-1 viral miRNAs miR-H28 and miR-H29 are also incorporated into EVs. These have 
been shown to have a pro-viral role in infection and facilitate infection in neighboring 
cells153, perhaps by weakening innate immune defenses. Further studies are needed to fully 
understand this observation, but it seems counterintuitive that the same infected cell would 
secrete pro-viral and antiviral EVs at the same time. More likely, these distinct effects 
identified in cultured cell lines represent different steps in natural infection perhaps by 
altering initial infection of different cell types, enhancing or limiting systemic spread 
throughout the host, or by altering viral virulence to facilitate persistence or establishment of 
latency. In sum, herpesviruses, by virtue of their large genomes (encoding > 100 proteins, as 
well as miRNAs and lncRNAs 154) modulate EV biogenesis and EV function through 
multiple independent mechanisms.
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Summary and outlook
In this Review, we have discussed the multiple ways in which different viruses manipulate 
EVs for their benefit in order to increase their persistence, pathogenesis, and transmission. In 
recent years EVs have emerged as specific carriers of cellular and viral components 
including miRNAs, proteins, and viral genomes. This can happen during active viral 
replication or during viral latency. The majority of experiments that have been performed 
explore how EVs can deliver cytoplasmic content from one cell to the cells in the 
surrounding environment in the absence of cell-cell fusion. However, the role of EVs can 
also be more far-reaching than the local environment in which they are released into (Figure 
4); the presence of EVs in blood and the lymphatic system suggests that EVs are able to 
transmit cargo over long distances.
The role of EVs in viral pathogenesis is similar to the role of EVs in cancer metastasis, 
where they are known to prime distant sites (soil) for reception of metastatic cells (seed) 
(See Box). EVs and their effects on recipient cells are mediated by individual EVs and the 
recipient cells do not produce and amplify these EVs. This is in contrast to virally infected 
cell which can produce thousands of viruses from a single infected cell (Figure 1) However, 
during chronic or latent viral infection a single infected cell may actually release EVs orders 
of magnitude greater than infectious viral particles, therefore the utilization of EVs to prime 
and enhance systemic viral infection is likely.
Experimental data that supports a role for EVs in priming the innate immune response has 
been reported. Cargo in EVs can elicit a TLR-dependent immune response in mice that have 
tumors155 or prime neighboring cells, including DCs, to respond to viral infection by 
priming the adaptive response or by releasing interferon 134,156. During this scenario, EVs 
may have evolved a role in the protection from pathogens, perhaps through the activation of 
innate immune responses in neighboring cells. A role for EVs in adaptive immunity has 
already been established, in which EVs (or some specialized membrane encapsulated 
vesicles) can efficiently cross-prime innate immunity and adaptive immune memory 
responses 27,28,30,101,157.
Importantly, it is likely that the basic research in EV biogenesis and fusion will be enhanced 
by previous, similar studies that characterized virion egress and entry. Many steps in the 
biogenesis of EVs are also used by viruses for entry and egress, for example, the ESCRT 
family of proteins. Further study of viral effects on the pathways that involve EVs is likely to 
identify the critical regulators of endosomal and exosomal trafficking in host cell physiology 
as well as new mechanisms that modulate the infection of a complex organism through 
enhancing and inhibitory effects on the infecting virus and resultant viability of the infected 
host cell. The further study of EV biology provides a rich area to enhance our understanding 
of the complexities of viral redirection of cellular processes and the determination of how 
viral effects on EV production and content contribute to both viral pathogenesis and 
persistence.
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Glossary
Capsid
Proteins that encapsulate viral genomes. Capsids are rigid, highly structured and are similar 
to crystals with a defined symmetry. The size, shape and symmetry of the capsid can be 
determined by electron microscopy and is sometimes used to classify viruses into taxa.
Endosomal sorting complex required for transport (ESCRT) machinery
A multi-protein complex that is involved in membrane vesicle biogenesis. Viruses use the 
ESCRT machinery to assemble virions and bud
Nanotubes
Membranous protrusions that connect adjacent cells over extended distances (up to 100 μM) 
and can transfer cellular components and viruses.
Cross-priming
Transfer of antigens from one cell to another, often to a professional antigen presenting cell, 
that does not make the antigen; the phrase was originally coined to explain counter-intuitive 
aspects of T cell responses.
Latent infection
Long-term presence of viral genomes (DNA or RNA) in a cell without evidence of virion 
production, for example, HIV integrated into the host genome or herpesvirus plasmids 
located in the nucleus. To differentiate latent from abortive or non-productive infection 
events, reactivation and subsequent release of virion particles is required for latent infection. 
Viral genomic material (RNA) that is transmitted by EVs can only lead to abortive infection.
Paracrine
Affecting the physiology of neighboring cells without cell-to-cell contact, typically by 
cytokines or growth factors. If the growth factors act on the same cell, that they originate 
from the process is called autocrine loop.
Persistent infection or chronic infection
Long-term presence of viral genomic information (DNA or RNA) in a cell or person with 
evidence of virus production and circulating infectious particles, but at a much lower level 
than observed during initial (primary) infection.
Autophagy
Autophagy is a regulated mechanism to provide nutrients through digestion of intracellular 
organelles, is utilized in different ways in the egress of multiple viruses.
Biomarker
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Protein, mRNA or other small molecule that can be measured and that is associated with 
disease outcome either independent of treatment (prognostic) or in relation to treatment 
(predictive).
Multivesicular bodies (MVB)
Are structures below the plasma membrane that serve as the central hub for sorting of 
molecules into other specialized compartments, as well as in and out of the cell.
Sphingomyelinase (EC 3.1.4.12)
Enzyme involved in the synthesized of sphingomyelin.
endosomal sorting complex required for transport (ESCRT)
A structure below the plasma membrane that serves to remodel the plasma membrane for the 
purpose for exporting macromolecules and membrane proteins.
RGD motif
The tripeptide Arg-Gly-Asp (RGD) is recognized by many integrins either as part of a short 
peptide (blocking peptide) or as repeat region in extracellular matrix proteins.
Hyperimmune serum
Serum obtained from one or many infected, convalescent animals that contains high levels of 
blocking antibodies to the target virus.
Cytopathic effect
Measure of infectious virus on monolayer cells.
Trojan Horse hypothesis
Initially introduced by Gould23 this hypothesis posits (a) an evolutionary relationship 
between retrovirus particle biogenesis and EV biogenesis and (b) the utility of this 
relationship as an alternative means to transfer viruses, or virus proteins and RNAs to 
neighboring cells independently of virion maturation and thereby unseen by the host 
immune response.
Interstitial spaces
Small, narrow spaces between tissues, which are typically filled with interstitial liquid.
Angiogenesis
Process of vessel growth into an organ carrying either blood or lymph, involving the 
migration, growth, and differentiation of endothelial cells
Principal component analysis
Statistical method to uncover relationships defined by 10–1000 or more correlated variables, 
which identifies those factors that contribute to variability. Typically the first 3–5 principal 
components are composed of those variables which have the greatest explanatory power.
Hierarchical cluster analysis
Statistical method to visualize relationships among variables and samples. Samples that on 
the basis of multiple variables are most similar are arranged together.
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Spectral counting
Method that determines the relative presence or absence of a peptide in a pair of samples 
analyzed by mass spectroscopy methods
Gene ontology
Fixed vocabulary of cellular processes and molecules that defines concepts/classes used to 
describe gene function, and relationships between these concepts.
Primary effusion lymphoma
Diffuse large B cell lymphoma that is caused by Kaposi’s sarcoma associated herpesvirus.
Crowding agents
Chemicals such as polyethylene glycol or acetone that change the availability of free solvent 
for proteins and other macromolecular structures with the result of causing aggregation.
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Box 2
EVs in cancer
Approximately 20%-30% of all cancers are associated with viral infections and many 
features of cancer are also features of viral infection, such as dissemination (metastasis in 
cancer), uncontrolled DNA replication and metabolic perturbation (for example, 
glycolysis and nucleotide biogenesis). Hence, insights that are gained from studying the 
physiological phenotypes of EVs in the context of cancer and metastasis could also be 
relevant to understanding the role of EVs in viral persistence165. EVs have been 
extensively studied in cancer research as they are released in high levels from tumor 
cells73–76. The contents of EVs that are released from tumor cells mirror the contents 
within the producing cells and therefore, these EVs are useful biomarkers. Therefore, the 
identification and characterization of EVs within body fluids from ‘liquid biopsies’ 
provides a noninvasive diagnostic and prognostic indicator for cancer development and 
progression13,131. The identification of proteins such as p53, epidermal growth factor 
(EGF), and fibroblastic growth factor (FGF) in EVs suggests a contributing role for EVs 
in oncogenesis. EVs are able to transfer proteins from malignant cells to neighboring or 
to distant cells, which can promote cancer growth through potential effects on the 
microenvironment, inhibition of the anti-cancer immune responses, and induction of 
angiogenesis. Interestingly, EVs have also been shown to facilitate metastasis by inducing 
epithelial to mesenchymal transition (EMT) and other changes within the target 
microenvironment73–75.
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Key points
• The considerable biochemical and physical similarity between viruses and 
exosomes complicates exosome purification. Both exosomes and viruses 
utilize the host vesicle trafficking machinery and therefore contain multiple 
proteins enriched in extracellular vesicles and viruses.
• Viruses have specific receptors and therefore usually have a more restricted 
repertoire of cells that permit viral entry. In contrast, exosome uptake is 
almost universal and can occur through several cellular endocytosis 
mechanisms in addition to direct fusion, a property that enables systemic 
delivery of exosome content.
• The differences in viral vs. exosome receptor usage can be used to separate 
and purify exosomes. This enables the identification of specific exosome-
mediated effects and provides a mechanism to test novel compounds to inhibit 
exosome delivery and function.
• Viruses that establish chronic, persistent infections within the infected host 
likely utilize exosomes to enhance establishment and maintenance of 
infection. The exosomes produced from virus-infected cells may also restrict 
virus infection perhaps to enable continued host viability and persistent viral 
infection.
• Exosomes are also abundantly produced by malignant cells and have been 
shown to facilitate tumorigenesis and metastasis through effects on the tumor 
environment. Similarly, tumor viruses such as KSHV and EBV manipulate 
exosome content to enhance viral transformation and maintenance of latency.
• The non-enveloped small RNA viruses including picornaviruses and Hepatitis 
A virus may acquire a membrane envelope through exosome secretion. This 
would inhibit recognition of viral proteins by the immune system and 
facilitate spread within the host.
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Figure 1. 
Protein complexes in the EV maturation pathway that are modulated during viral infection. 
Shown are the principal egress pathways of a cell starting with the nucleus. The late 
endosome or MVB sorts contents from the early endosome into either the lysosome or EVs 
for egress. The early endosome is the first step in vesicle uptake and recycling. The 
individual molecules identified here have demonstrated functions in EVs or virus 
maturation.
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Figure 2. 
Modes of virus-EV interaction. The different panels representing different viruses (HCV, 
HAV, HIV, EBV and KSHV). For each virus a virion-dependent transfer and the EVs 
dependent transfer step is shown. Only in the case of HCV and HAV have entire virions 
been identified within EVs. For the other viruses, only individual RNAs or proteins, but 
never the whole genome is seen in EVs. In case of EBV many different moieties are 
transmitted via EVs from infected cells: cellular proteins, viral proteins cellular miRNAs, 
viral miRNAs as well as other small viral RNAs and RNA breakdown products. In case of 
KSHV (E) the cartoon exemplifies a temporal model, whereby viral miRNAs transmitted by 
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EVs precede infection by a viral particle (Step 1) and thus may prepare the recipient cells for 
infection (Step 2)
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Figure 3. 
A. Separation of EVs from virions by positive selection. First, particles are concentrated on 
the basis of biophysical properties such as density, size and/or weight. Most virions co-
purify with EVs under these conditions. Next, EVs are positively selected using anti-EV 
surface antibodies and virions, which do not contain these markers, are in the column flow-
through. The reverse experiment (not shown) is possible as well, namely were virions are 
selected positively and EVs are present in the flow-through. P, pellet after filtration and 
differential ultracentrifugation (UC); S, supernatant, E, pellet of EVs and virions. B. 
Electron micrograph (EM) of EV. Shown is a surface EM picture of tumor cell line derived 
EVs after isolation and silver staining (courtesy of P.Chugh, S.Ozgur and J.Griffith).
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Figure 4. 
Conceptual difference between (A) viruses and (B) EVs. Cells are indicated as disks. Spread 
is indicated by black connecting arrows. Red indicates amplification of input material 
(virus), green indicates delivery (EV) without subsequent amplification. The upper two 
panels refer to local spread, i.e. within a tissue or microenvironment and the lower panels 
refer to systemic spread via blood, lymph or interstitial fluids. Upon virus infection the 
signal (i.e. virus derived miRNAs and proteins) is amplified in each permissive cell and over 
time the number of altered cells increases. Upon EVs absorption no amplification takes 
place and any phenotype caused by EVs is diffusion-limited. Only cells directly exposed to 
EVs in the circulation, which are mostly endothelial cells, can be modulated by EVs.
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Table 1
Prominent EV markers and EV associated viral proteins.
Location Protein* [Au:* OK? above refers to 
protein?]
Structural Class Function
Surface exposed 
on EVs
CD9 Tetraspanin Cell adhesion
CD63 Tetraspanin Cell signaling
CD81 Tetraspanin Cell signaling, proliferation 
marker
MHC-I Histocompatibility antigen, class I Antigen presentation
MHC-II Histocompatibility antigen, class II Antigen presentation
CD86 Type I membrane protein, IgG 
superfamily
CTLA-4 Counter-Receptor B7.2
FLOT1 Integral membrane component of 
caveolae
Scaffolding protein for vesicle 
formation
ANXA5 calcium-dependent phospholipid 
binding protein (Annexin)
Phospholipid binding
Internal to EVs HSP70 heat shock protein Mediates folding
HSP90 heat shock protein Mediates folding
ALIX PDCD6-Interacting Protein ESCRT pathway
TSG101 - ESCRT pathway, tumor 
suppressor
Virus EBV LMP1 Membrane protein Cell signaling/CD40 analog
EBV LMP2a Membrane protein Cell signaling
EBV gp350 Membrane/virion protein Receptor binding
HIV Nef Membrane protein CD4, MHC-I downregulation
HSV-1 gB Membrane/virion protein Receptor binding
Vaccina virus glycoproteins Membrane/virion protein Receptor binding
HCV (whole virus) virus (flavivirus), enveloped infection
HAV (whole virus) Virus (picornavirus), non-enveloped infection
Poliovirus, Coxsackievirus,, Rhinovirus Virus (picornavirus), non-enveloped infection
*
Based on information in 10,166 and www.exocarta.org. Note that not all markers are present in all EVs as demonstrated by comprehensive 
MS/MS analyses12
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